Intravascular catheters are the most common cause of nosocomially acquired bloodstream infections. Bacteria found adhering to the intraluminal surfaces of catheters are the principal source and cause of these infections. Adherent bacteria overtime are known to form multicellular communities which become encased within a three dimensional matrix of extracellular polymeric material known as biofilms, which are thought to be responsible for persistent infections. Consequently, a number of technologies have been developed to help prevent and control biofilms in intravascular catheters. One such approach involves impregnating catheter material with antimicrobial agents. Unfortunately these methods are not universally effective in preventing catheter-related biofilm infections. Technologies that utilise antimicrobials, as catheter locks have been shown to have more potential for preventing biofilm formation and reducing the incidences of catheter related bloodstream infections (CRBSI). This article discusses the significance of biofilms in intravascular catheters and determines whether the treatments available today are proving to be effective for controlling biofilms and draws attention to future avenues which are being investigated to control biofilms and therefore CRBSI.
BacuzziA., CecchinA., Del BoscoA., CantoneG., CuffariS.Recommendations and reports about central venous catheter-related infection.Surg Infect (Larchmt)2006; 7: S65–7.
2.
RichardsM., EdwardsJ., CulverD., GaynesR.Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.Crit Care Med1999; 27: 887–92.
3.
Anon. Guidelines for the prevention of intravascular catheter-related infections.MMWR Morb Mortal Wkly Rep2002; 51: 1–29.
4.
MarrK.A., SextonD.J., ConlonP.J., CoreyG.R., SchwabS.J., KirklandK.B.Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing haemodialysis.Ann Intern Med1997; 127: 275–80.
5.
CostertonJ., StewartP., GreenbergE.Bacterial biofilms: a common cause of persistent infections.Science1999; 284: 1318–22.
6.
AnaissieE., SamonisG., KontoyiannisD.Role of catheter colonization and infrequent hematogenous seeding in catheter-related infections.Eur J Clin Microbiol Infect Dis1995; 14: 134–7.
7.
RaadI., CostertonW., SabharwalU., SacilowskiM., AnaissieE., BodeyG.Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement.J Infect Dis1993; 168: 400–7.
8.
PittetD., TararaD., WenzelR.Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality.JAMA1994; 271: 1598–1601.
9.
MakiD.G.Yes, Virginia, aseptic technique is very important: maximal barrier precautions during insertion reduce the risk of central venous catheter-related bacteremia.Infect Control Hosp Epidemiol1994; 15: 227–30.
10.
DarouicheR.Device-associated infections: a macro-problem that starts with microadherence.Clin Infect Dis2001; 33: 1567–72.
11.
MermelL.A.Prevention of intravascular catheter-related infections.Ann Intern Med2000; 132: 391–402.
12.
PittetD.Nosocomial bloodstream infections. In: WenzelR.P., ed. Prevention and control of nosocomial infections.3rd ed.Baltimore, MD: Lippincott, Williams and Wilkins, 1997: 711–69.
13.
SnydmanD.R.Prevention of catheter and intravascular device-related infections: a quality-of-care mandate for institutions and physicians.Mayo Clin Proc2006; 81: 1151–2.
14.
CrinchC., MakiD.The promise of novel technology for the prevention of intravascular device-related bloodstream infection, I: pathogenesis and short-term devices.Clin Infect Dis2002; 34: 1232–42.
15.
MakiD.G., StolzS.M., WheelerS., MermelL.A.1997. Prevention of central venous catheters-realted bloodstream infection by use of an antiseptic-impregnated catheter: randomised, controlled trial.Ann Intern Med1997; 127: 257–66.
16.
EdgeworthJ.D., TreacherD.F., EykynS.J.A 25-year study of nosocomial bacteremia in an adult intensive care unit.Crit Care Med1999; 27: 1421–8.
17.
LinaresJ., Sitges-SerraA., GarauJ., PerezJ.L., MartinR.Pathogenesis of catheter sepsis: a prospective study with quantitative and semi quantitative cultures of catheter hub and segments.J Clin Microbiol1985; 21: 357–60.
18.
MermelL., StolzS., MakiD.G.Epidemiology and pathogenesis of infection with Swan-Ganz catheters: a prospective study utilizing molecular subtyping.Am J Med1991; 91(3B): 197S–205S.
19.
ConlyJ., SteinK., PetersB.The pathogenesis of catheter-related infection in central venous catheters using gauze versus transparent dressings. In: WadstromT., EliassonI., HolderI., LjunghA. eds. Pathogenesis of wound and biomaterial associated infections.London: Springer Verlag, 1990: 508–17.
20.
O'GradyN.P.Guidelines for the prevention of intravascular catheter-related infections.Am J Infect Control2002; 30: 476–89.
MarcianteK.D., VeenstraD.L., LipskyB.A.2003. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use.Am J Infect Control2003; 31: 1.
RichardsM.J., EdwardsJ.R., CulverD.H., GaynesR.P.Nosocomial infections in coronary care units in the United States. National Nosocomial Infections Surveillance System.Am J Cardiol1998; 82: 789–93.
RelloJ., OchagaviaA., SabanesE.Evaluation of outcome of intravenous catheter-related infection in critically ill patients.Am J Resp Crit Care Med2000; 162: 1027.
27.
SherertzR.J.Pathogenesis of vascular catheter infections. In: WaldvogelF. A., and BisnoA. L., eds. Infections associated with indwelling medical devices, 3rd ed.Washington: ASM Press, D.C.2000; 111–25.
28.
CharacklisW.G., McFetersG.A., MarshallK.C.1990Physiological ecology in biofilm systems, p 341–394. In: CharacklisWG, ad MarshallK.C. (ed.) Biofilms.John Wiley and Sons Inc, New York.
29.
AppelgrenP., RansjoU., BindslevL., EspersenF., LarmO.Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial.Crit Care Med1996; 24: 1482–9.
30.
HerrmannM.Fibronectin, fibrinogen and laminin act as mediators of adherence of clinical staphylococcocal isolates to foreign material.J Infect Dis1988; 158: 693–701.
31.
NilssonM., FrykbergL., FlockJ.L., PeiL., LindbergM., GussB.A fibrinogen-binding protein of Staphylococus epidermidis.Infect Immun1998; 66: 2666–73.
32.
DeMuriG.P., HostetterM.K.Evidence for B1 integrin fibronectin receptor in Candida tropicalis.J Infect Dis1996; 174: 127–32.
33.
PasseriniL., LanK., CostertonJ., KingE.Biofilms on indwelling vascular catheters.Crit Care Med1992; 20: 665–73.
34.
PercivalS.L., BowlerP.Biofilms and their potential role in wound healing.Wounds2004; 16: 234–40.
35.
MossA.H., VasilakisC., HolleyJ.L., FoulksC.J., PillaiK., McDowellD.E.Use of a silicone dual lumen catheter with a Darcon cuff as a long term vascular access for hemodialysis patients.Am J Kidney Dis1990; 16: 211–5.
PascualA., Ramirez de ArellanoE., Martinez-MartinezL., PereaE.J.Effect of polyurethane catheters and bacterial biofilms on the in vitro activity of antimicrobial agents against Staphylococcus epidermidis.J Hosp Infect1993; 24: 211–8.
38.
Ramirez de ArellanoE., PascualA., Martinez MartinezL., PereaE.J.Activity of eight antibacterial agents on Staphylococcus epidermidis attached to Teflon catheters.J Med Microbiol1994; 40: 43–7.
39.
ParrasF., EnaJ., BouzaE.Impact of an educational program for the prevention of colonization of intravascular catheters.Infect Control Hosp Epidemiol1994; 15: 239–42.
40.
EnaJ., CercenadoE., MartinezD., BouzaE.Cross-sectional epidemiology of phlebitis and catheter-related infections.Infect Control Hosp Epidemiol1992; 13: 15–20.
41.
SafdarN., MarxJ., MeyerN.A., MakiD.G.Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit.Am J Infect Control2006; 34: 476–83.
42.
MoroM.L., ViganoE.F., Cozzi LepriA.Risk factors for central venous catheter-related infections in surgical and intensive care units. The Central Venous Catheter-Related Infections Study Group.Infect Control Hosp Epidemiol1994; 15: 253–64.
43.
HoffmanK.K., WeberD.J., SamsaG.P., RutalaW.A.Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks.JAMA1992; 267: 2072–6.
44.
HannanM., JusteR.N., UmasankerS.Antispetic-bonded central venous catheters and bacterial colonization.Anaesthesia1999; 54: 868–72.
45.
LooS., van HeerdenP.V., GolleegeC.V., RobertsB.L., PowerB.M.Infection in central lines: antiseptic-impregnated vs. standard non-impregnated catheters.Anaesth Intens Care1997; 25: 637–9.
46.
ShengW.H., KoW.J., WangJ.T., ChangS.C., HsuehP.R., LuhK.T.Evaluation of antiseptic-impregnanted central venous catheters for prevention of catheter-related infection in intensive care unit patients.Diagn Microbiol Infect Dis2000; 38: 1–5.
47.
LoggheC., Van-OsselC., D'HooreW., EzzedineH., WautersG., HaxheJ.J.Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for prevention of bloodstream infection in leukaemic patients: a randomized controlled trial.J Hosp Infect1997; 37: 145–56.
48.
MakiD., RingerM., AlvaradoC.Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters.Lancet1991; 338: 339–43.
49.
SoiferN., BorzakS., EdlinB., WeinsteinR.Prevention of peripheral venous catheter complications with an intravenous therapy team.Arch Intern Med1998; 158: 473–7.
50.
ModakS.M., SampathL.Development and evaluation of a new polyurethane central venous antiseptic catheter: reducing central venous catheter infections.Complications in Surgery1992; 11: 23–9.
51.
SampathL.A., TambeS.M., ModakS.M.In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheter.Infect Control Hosp Epidemiol2001; 22: 640–6.
52.
GreenfieldJ.L., SampathL., PopilskisS.J., BrunnertSR, StylianosS., ModakS.Decreased bacterial adherence and biofilm formation on chlorhexidine and silver sulfadiazine impregnated central venous catheters implanted in swine.Crit Care Med1995; 23: 894–900.
53.
SampathL.A., ChowdhuryN., CaraosL., ModakS.M.Infection resistance of surface modified catheters with either short-lived or prolonged activity.J Hosp Infect1995; 30: 201–10.
54.
VeenstraD., SaintS., SahaS., LumleyT., SullivanS.Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection.JAMA1999; 281: 261–7.
55.
TrooskinS.Z., DonetzA.P., HarveyR.A., GrecoR.S.Prevention of catheter sepsis by antibiotic bonding.Surgery1985; 97: 547–51.
56.
DarouicheR., RaadI., HeardS.A comparison of two antimicrobial-impregnated central venous catheters.N Engl J Med1999; 340: 1–8.
57.
HeardS.O., WagleM., VijayakumarE.Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia.Arch Intern Med1998; 158: 81–7.
58.
BachA., SchmidtH., BottigerB.Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters.J Antimicrob Chemother1996; 37: 315–22.
59.
TennenbergS., LeserM., McCurdyB.A prospective randomized trial of an antibiotic and antiseptic coated central venous catheter in the prevention of catheter related infection.Arch Surg1997; 132: 1348–51.
60.
GeorgeS.J., VuddamalayP., BoscoeM.J.Antiseptic-impregnanted cental venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients.Eur J Anaesthesiol1997; 14: 428–31.
YorganciK., KrepelC., WeigeltJ.A., EdmistonC.In vitro activity of three different types of antibiotic/antibacterial coated/integrated central venous catheters against Gram-positive bacteria.Clin Microbiol Infect2001; 7: 219.
63.
WalderB., PittetD., TramerM.R.Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis.Infect Control Hosp Epidemiol2002; 23: 748–56.
64.
ChatzinikolaouI., FinkelK., HannaH.Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study.Am J Med2003; 115: 352–7.
65.
TacconelleE., TumbarelloM., CaudaR.Central venous catheters and bloodstream infection.JAMA2000; 283: 478–9.
66.
CollinG.R.Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continous quality improvement project.Chest1999; 115: 1632–40.
67.
VeenstraD., SaintS., SullivanS.Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection.JAMA1999; 282: 554–60.
68.
LoertzerH., SoukupJ., HamzaA.Use of catheters with the AgION antimicrobial system in kidney transplant recipients to reduce infection risk.Transplant Proc2006; 38: 707–10.
69.
StoiserB., KoflerJ., StaudingerT.Contamination of central venous catheters in immunocompromised patients: a comparison between two different types of central vevous catheters.J Hosp Infect2002; 50: 202–6.
70.
BongJ.J., KiteP., WilcoxM.H., McMahonM.J.Prevention of catheter related bloodstream infection by silver iotophoretic central venous catheters: a randomised control trial.J Clin Pathol2003; 56: 731–5.
71.
OsmaS., KahveciS.F., KayaF.N.Efficacy of antiseptic-impregnated catheters on catheter colonization and catheter-related bloodstream infections in patients in an intensive care unit.J Hosp Infect2006; 62: 156–62.
72.
MossH.A., TebbsS.E., FaroquiM.H.A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization.Eur J Anaesthesiol2000; 17: 680–7.
73.
OdaT., HamasakiJ., KandaN., MikamiK.Anaphylactic shock induced by an antiseptic-coated central nervous (sic venous) catheter.Anesthesiology1997; 87: 1242–4.
74.
Anon.Centers for Devices and Radiological Health, US Food and Drug Administration.FDA public health notice: potential hypersensitivity reactions to chlorhexidine-impregnated medical devices.1998. Available at: http://www.fda.gov/cdrh/chlorhex.html.
75.
RaadI., DarouicheR., HachemR., MansouriM., BodeyG.P.The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin.J Infect Dis1996; 173: 418–24.
76.
VercaigneL.M., ZelenitskyS.A., FindlayI., BernsteinK., PennerS.B.An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters.J Antimicrob Chemother2002; 49: 693–6.
77.
ManierskiC., BesarabA.Antimicrobial locks: putting the lock on catheter infections.Adv Chronic Kidney Dis2006; 13: 245–58.
78.
NoriU.S., ManoharanA., YeeJ., BesarabA.Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia.Am J Kidney Dis2006; 48: 596–605.
79.
FortunJ., GrillF., Martin-DavilaP.Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy.J Antimicrob Chemother2006; 58: 816–21.
80.
LeeJ.Y., KoK.S., PeckK.R., OhW.S., SongJ.H.In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci.J Antimicrob Chemother2006; 57: 1110–5.
81.
Segarra-NewnhamM., Martin-CooperE.M.Antibiotic lock technique: a review of the literature.Ann Pharmacother2005; 39: 311–8.
82.
CarratalàJ., NiubóJ., Fernández-SevillaA.Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer.Antimicrob Agents Chemother1999; 43: 2200–4
83.
HenricksonK.J., AxtellR.A., HooverS.M.Prevention of central venous catheter-related infections and the thrombotic events in immunocompromised children by the use of vancomycin/ ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial.J Clin Oncol2000; 18: 1269–78.
84.
RubieH., JuricicM., ClaeyssensS.Morbidity using subcutaneous ports and efficacy of vancomycin flushing in cancer.Arch Dis Child1995; 72: 325–9.
85.
SchwartzC., HenricksonK.J., RoghmannK., PowellK.Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms.J Clin Oncol1990; 8: 1591–7.
86.
SherertzR.J., BogerM.S., CollinsC.A., MasonL., RaadI.Comparative in vitro efficacies of various catheter lock solutionsAntimicrob Agents Chemother2006; 50: 1865–8.
87.
RaadI., HannaH., DvorakT., ChaibanG., HachemR.Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.Antimicrob Agents Chemother2007; 51: 78–83.
88.
JurewitschB.Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections.J Parenter Enteral Nutr1998; 22: 242–4.
89.
ShahC.B., MittelmanM.W., CostertonJ.W.Antimicrobial activity of a novel catheter lock solution.Antimicrob Agents Chemother2002; 46: 1674–9.
90.
BedrosianI., SofiaR.D., WolffS.M., DinarelloC.A.Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumour necrosis factor synthesis in human peripheral blood mononuclear cells.Cytokine1991; 3: 568–75.
91.
BrowneM.K., LeslieG.B., PfirrmannR.W.Taurolin, a new chemotherapeutic agent.J Appl Bacteriol1976; 41: 363–8.
92.
GormanS.P., McCaffertyD.F., WolfsonA.D., JonesD.S.Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with taurolin, a novel antimicrobial agent.J Appl Bacteriol1987; 62: 315–20.
93.
Torres-VieraC., Thauvin-EliopoulosC., SouliM.Activities of taurolidine in vitro and in experimental enterococcal endocarditis.Antimicrob Agents Chemother2000; 44: 1720–4.
94.
AldersonL., SampathP., DarnowskiJ.W., CalabresiP.Phase I/II clinical and pharmacologic studies with taurolidine in patients with recurrent glioblastoma multiforme. Abstracts of the 2001 American Society of Clinical Oncology Annual Meeting, abstr. 2061. 18 Dec 2005.
95.
RutalaW.A., BarbeeS.L., AguiarN.C., SobseyM.D., WeberD.J.Antimicrobial activity of home disinfectants and natural products against potential human pathogens.Infect Control Hosp Epidemiol2000; 21: 33–8.
96.
DannenbergC., BierbachU., RotheA., BeerJ., KorholzD.Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheters.J Pediatr Hematol Oncol2003; 25: 616–21.
97.
Anonymous. 10 June 2005, accession date. Ethanol. Micromedex Healthcare Series, vol. 124. Thomson Micromedex, Greenwood Village, Colorado.
98.
FlemingM., MihicS.J., HarrisR.A.Ethanol. In: HardmanJ.G., LimbirdL.E., eds. Goodman and Gillman's the pharmacological basis of therapeutics, 3rd ed.New York: N.Y. McGraw-Hill, 2001; p. 429–45.
99.
SissonsC.H., WongL., CutressT.W.Inhibition by ethanol of the growth of biofilm and dispersed microcosm dental plaques.Arch Oral Biol1996; 41: 27–34.
100.
OnlandW., ShinC.E., FustarS., RushingT., WongW.Y.Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients.Arch Pediatr Adolesc Med2006; 160: 1049–53.
101.
PenningtonC.R., PithieA.D.Ethanol lock in the management of catheter occlusion.J Parenter Enteral Nutr1987; 11: 507–8.
RaadI., LunaM., KhalilS.A., CostertonJ.W., LamC., BodeyG.P.The relationship between the thrombotic and infectious complications of central venous catheters.JAMA1994; 271: 1014–6.
104.
TimsitJ.F., FarkasJ.C., BoyerJ.M.Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis.Chest1998; 114: 207–13
105.
WerlinS.L., LaustenT., JessenS.Treatment of central venous catheter occlusions with ethanol and hydrochloric acid.J Parenter Enteral Nutr1995; 19: 416–8.
ReinmullerJ.The influence of taurolidine on physiological and pathological blood coagulation and implications for its use.Zentralbl Chir1999; 124: 13–18.
108.
MetcalfS.C.L., ChambersS.T., PithieA.D.Use of ethanol locks to prevent recurrent central line sepsis.J Infect Volume2004; 49: 20–2.
109.
MandolfoS., BorlandelliS., ElliA.Catheter lock solutions: it's time for a change.J Vasc Access2006; 7: 99–102.
110.
GrudzinskiL., QuinanP., KwokS., PierratosA.Sodium citrate 4% locking solution for central venous dialysis catheters -an effective, more cost-efficient alternative to heparin.Nephrol Dial Transplant2007; 22: 471–6.
111.
AshS.R.Concentrated sodium citrate (23%) for catheter lock.Hemodialysis Int2000; 4: 22–31.
112.
SodemannK., PolascheggH.D., FeldmerB.Two years' experience with Dialock® and CLS™ (a new antimicrobial lock solution).Blood Purif2001; 19: 251–4.
113.
SodemannK.Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and /or salts thereof. US Patent No 6, 166, 007, Issued Dec 26, 2000.
114.
Torres-VieraC., Thauvin-EliopoulosC., SouliM.Activities of taurolidine in vitro and in experimental enterococcal endocarditis.Antimicrob Agents Chemother2000; 44: 1720–2000.
115.
MittlemanM.W., PelakM., ShahC., CostertonJ.W.Eradication of microbial biofilms with an antimicrobial catheter-lock solution (abstract) General Meeting of American Society of Microbiology, May 2001.
116.
MermelL.A., ParenteauS.Efficacy of the Biolink Catheter Lock Solution (CLS™) for Dialock® hemodialysis access port and catheters - An in vitro model (abstract). 4th Devennial International Conference on Nosocomial and Healthcare-Associated Infections, March 2000.
LokC.E., AppletonD., BholaC., KhooB., RichardsonR.M.Trisodium citrate 4% - an alternative to heparin capping of haemodialysis catheters.Nephrol Dial Transplant2007; 22: 477–83.
119.
KiteP., EastwoodK., SugdenS., PercivalS.L.Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro.J Clin Microbiol2004; 42: 3073–6.
120.
KiteP., EastwoodK., PercivalS.L.Catheters and control of infection. In: McBainA., AllisonD., PrattenJ., SprattD., UptonM., VerranJ., eds. Biofilms, Persistence and Ubiquity, 2005. September 6–8th, Bioline, Cardiff.
121.
RileyM.A., WertzJ.E.Bacteriocins: Evolution, ecology, and application.Annu Rev Microbiol2002; 56: 117–37.
122.
FontanaM.B.C., Basto Freire deM.D.C., BrandelliA.Bacteriocins Pep5 and Epidermin inhibit Staphylococus epidermidis adhesion to catheters.Current Microbiology2006; 52: 350–3.
123.
CurtinJ.J., DonlanR.M.Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis.Antimicrob Agents Chemother2006; 50: 1268–75.
124.
RussellA.D., DayM.J.Antibiotics and biocide resistance in bacteria.Microbios1996; 85: 45–65.
125.
RussellA.D., UnchaleeT., MaillardJ.Y., FurrJ.R.Possible link between bacterial resistance and the use of antibiotics and biocides.Antimicrob Agents Chemother1998; 42: 2151.
126.
PercivalS.L., KiteP., EastwoodK.Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm.Infect Control Hosp Epidemiol2005; 26: 515–9.
127.
RaadI., BuzaidA., RhyneJ.Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections.Clin Infect Dis1997; 25: 149–51.
128.
BassettiS., DAgostinoR., SherertzR.Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo.Antimicrob Agents Chemother2001; 45: 1535–8.
129.
TambeS.M., SampathL., ModakS.M.In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices.J Antimicrob Chemother2001: 47: 589–98.
130.
MunsonE.L., HeardS.O., DoernG.V.In vitro exposure of bacteria to antimicrobial impregnated central venous catheters does not directly lead to the emergence of antimicrobial resistance.Chest2004; 126: 1628–35.
131.
WarrenD.K., ZackJ.E., MayfieldJ.L.The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU.Chest2004; 126: 1612–8.
132.
SteeleL., SolomonS., KritchevskyS.Correlation between HICPAC recommendations for the prevention of intravascular device-related infections and reported practices in 53 hospitals participating in the evaluation of processes and indicators in infections control study [abstract].Am J Infect Control2000; 28: 89.
